Loading chat...
NJ A1816
Bill
Status
1/13/2026
Primary Sponsor
Anthony Verrelli
Click for details
AI Summary
-
Requires New Jersey general acute care hospitals to include fentanyl and xylazine testing in all urine drug screenings conducted during patient treatment.
-
Mandates testing for any additional drugs subject to a public health alert from the Commissioner of Health regarding overdose risks from illicit use.
-
Hospitals must report de-identified positive test results for fentanyl, xylazine, or other alert-specified drugs to the Department of Health in a prescribed format.
-
Permits hospitals without urinalysis analyzer equipment to use fentanyl, xylazine, or other drug test strips to comply with testing requirements.
-
Takes effect 90 days after enactment.
Legislative Description
Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.
Health
Last Action
Introduced, Referred to Assembly Health Committee
1/13/2026